Integris Wealth Management LLC Buys 150 Shares of Abbott Laboratories (NYSE:ABT)

Integris Wealth Management LLC lifted its stake in Abbott Laboratories (NYSE:ABT) by 3.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,767 shares of the healthcare product maker’s stock after buying an additional 150 shares during the quarter. Integris Wealth Management LLC’s holdings in Abbott Laboratories were worth $539,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in ABT. Fortune Financial Advisors LLC raised its stake in Abbott Laboratories by 4.1% during the 4th quarter. Fortune Financial Advisors LLC now owns 11,291 shares of the healthcare product maker’s stock worth $1,277,000 after acquiring an additional 443 shares during the period. Hixon Zuercher LLC increased its stake in shares of Abbott Laboratories by 1.9% in the fourth quarter. Hixon Zuercher LLC now owns 23,068 shares of the healthcare product maker’s stock worth $2,609,000 after purchasing an additional 427 shares in the last quarter. Mediolanum International Funds Ltd raised its position in shares of Abbott Laboratories by 75.0% during the 4th quarter. Mediolanum International Funds Ltd now owns 314,605 shares of the healthcare product maker’s stock valued at $35,400,000 after purchasing an additional 134,803 shares during the period. Crews Bank & Trust purchased a new position in shares of Abbott Laboratories during the 4th quarter valued at $722,000. Finally, Cairn Investment Group Inc. boosted its holdings in Abbott Laboratories by 71.9% in the 4th quarter. Cairn Investment Group Inc. now owns 3,179 shares of the healthcare product maker’s stock worth $360,000 after buying an additional 1,330 shares during the period. 75.18% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Wells Fargo & Company raised their price target on Abbott Laboratories from $133.00 to $136.00 and gave the company an “overweight” rating in a report on Thursday, January 23rd. Raymond James reissued a “buy” rating and issued a $129.00 price target (up from $122.00) on shares of Abbott Laboratories in a report on Monday, October 14th. Evercore ISI increased their price objective on shares of Abbott Laboratories to $136.00 and gave the company a “buy” rating in a report on Thursday, January 2nd. Mizuho lifted their price objective on shares of Abbott Laboratories from $115.00 to $130.00 and gave the company a “neutral” rating in a research report on Thursday, October 17th. Finally, Stifel Nicolaus upped their target price on shares of Abbott Laboratories from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $133.06.

Abbott Laboratories Stock Up 0.7 %

Shares of ABT opened at $128.75 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32. The business has a fifty day moving average of $115.94 and a 200 day moving average of $113.90. The company has a market cap of $223.32 billion, a PE ratio of 16.83, a P/E/G ratio of 2.38 and a beta of 0.73. Abbott Laboratories has a 52-week low of $99.71 and a 52-week high of $129.85.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 EPS for the quarter, hitting analysts’ consensus estimates of $1.34. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The firm had revenue of $10.97 billion during the quarter, compared to analysts’ expectations of $11.03 billion. During the same period in the previous year, the company earned $1.19 EPS. The firm’s revenue for the quarter was up 7.2% compared to the same quarter last year. On average, sell-side analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be given a $0.59 dividend. This represents a $2.36 annualized dividend and a yield of 1.83%. The ex-dividend date of this dividend is Wednesday, January 15th. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.55. Abbott Laboratories’s dividend payout ratio is 30.85%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.